Discover our comprehensive platform of CDX and PDX tumor models, carrying BRAF mutations across multiple cancer types: 18 CDX models carrying BRAF mutation (V600E, G469A, G464V, G466V, G596R or N581Y), covering melanoma, breast cancer, lung cancer and colorectal cancer 18 PDX models carrying BRAF mutation (V600E, G469A, G469E, D594N or N581S), covering melanoma, pancreatic cancer, …Read More >

Leverage our extensive panel of rat xenograft and syngeneic tumor models. Advantages for using rats in preclinical efficacy studies compared with mice include: more similar metabolism and physiology to human; easier use for orthotopic model surgery, vascular manipulation, and imaging; larger sampling sizes to ensure sufficient amount for bioanalysis; consistent animal species to toxicology studies …Read More >

KRAS mutant proteins that drive cancer development are highly similar in sequence and structure. Direct inhibitors are most likely to bind to the catalytic domain of KRAS. However, recent studies have found that KRAS mutants can also be targeted by heterogeneous sites, to develop covalent inhibitors of KRAS mutants. The discovery of inhibitors that selectively …Read More >

Offering a comprehensive platform of in vitro imaging-based assays to screen compounds for cancer, inflammation, and autoimmune diseases. Our services include: Imaging assays for cell proliferation and apoptosis Imaging assays for cell cycle analysis Cell-based functional assays, including: Antibody internalization Live-cell immunocytochemistry Cellular movement and morphology monitoring Assays for 3D cell models, including: Spheroid growth …Read More >

Leverage our extensive panel of CDK4/6 inhibitor resistant breast cancer models, including:  In vitro induced Palbociclib resistant MCF-7 cell line In vivo induced Palbociclib resistant MCF-7 model In vivo induced Abemaciclib resistant MCF-7 model In vivo induced Ribociclib resistant MCF-7 model View additional drug-resistant models in our platform